Pharma's Next Top Model: Slimmer Business Models - Pharmaceutical Executive


Pharma's Next Top Model: Slimmer Business Models
The fat times are over. No excesses, no regrets. A slimmer business model makes any company beautiful.

Pharmaceutical Executive

If excessive legacy scale is a barrier to focus, re-basing remains an option—shedding non-core assets and aligning investment and capabilities around a related set of opportunities.

In the future, there will be no common model, no shared success template. As industry leaders learn to play by new rules, they will need to experiment more radically—not just with choices about channel, breadth, and disease focus, but also with choices involving geographic scope, product and service integration, and where to play in the value chain.

Jerry Cacciotti is managing director and Bill Shew is a principal of SDG's Life Science practice. he can be contacted at


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here